CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 78 filers reported holding CUE BIOPHARMA INC in Q2 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $67 | -74.3% | 18,269 | -75.0% | 0.01% | -73.1% |
| Q1 2023 | $261 | -51.4% | 73,111 | -61.2% | 0.03% | -61.2% |
| Q4 2022 | $537 | -99.9% | 188,308 | -12.9% | 0.07% | +4.7% |
| Q3 2022 | $482,000 | +49.2% | 216,250 | +66.8% | 0.06% | +33.3% |
| Q2 2022 | $323,000 | -31.4% | 129,666 | +34.3% | 0.05% | -23.8% |
| Q1 2022 | $471,000 | -58.3% | 96,563 | -3.3% | 0.06% | -55.6% |
| Q4 2021 | $1,129,000 | -36.4% | 99,816 | -18.0% | 0.14% | -21.5% |
| Q3 2021 | $1,774,000 | +436.0% | 121,727 | +328.7% | 0.18% | +389.2% |
| Q2 2021 | $331,000 | +113.5% | 28,396 | +124.2% | 0.04% | +42.3% |
| Q1 2021 | $155,000 | -80.7% | 12,666 | -80.3% | 0.03% | -80.3% |
| Q4 2020 | $804,000 | +19.3% | 64,297 | +43.5% | 0.13% | +17.9% |
| Q3 2020 | $674,000 | – | 44,801 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Corriente Advisors, LLC | 820,000 | $11,636,000 | 12.56% |
| Prosight Management, LP | 552,060 | $7,834,000 | 3.66% |
| Nantahala Capital Management | 2,503,840 | $35,529,000 | 1.33% |
| MANGROVE PARTNERS IM, LLC | 601,398 | $8,534,000 | 1.18% |
| Voss Capital, LLC | 88,670 | $749,000 | 1.00% |
| Slate Path Capital LP | 870,694 | $12,355,000 | 0.95% |
| Avoro Capital Advisors LLC | 1,870,000 | $26,535,000 | 0.90% |
| Bleichroeder LP | 165,000 | $2,341,000 | 0.61% |
| 683 Capital Management, LLC | 640,000 | $9,082,000 | 0.54% |
| PA Capital LLC | 40,706 | $578,000 | 0.51% |